Abuse potential of zomepirac

Rolley E. Johnson, Donald R. Jasinski, Theresa R. Kocher

Research output: Contribution to journalArticlepeer-review


Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

Original languageEnglish (US)
Pages (from-to)386-389
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number3
StatePublished - Sep 1983

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Abuse potential of zomepirac'. Together they form a unique fingerprint.

Cite this